Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey-Reference-Cited by-同舟云学术

Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey

Published:2024-04-25 Issue:3 Volume:206 Page:473-481
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Bradbury M.,Savard MF,Stober C.,Clemons L.,Clemons M.,Hilton J.,Pond G.,Vandermeer L.,McGee SF^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10549-024-07302-0.pdf

Reference29 articles.

1. Omarini C et al (2022) Jul., T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis, vol. 22, [Online]. Available: https://bmccancer.biomedcentral.com/articles/https://doi.org/10.1186/s12885-022-09556-7

2. Joensuu H et al (2018) Sep., Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer, JAMA Oncol, vol. 4, no. 9, pp. 1199–1206, https://doi.org/10.1001/jamaoncol.2018.1380

3. Slamon D et al (2011) Oct., Adjuvant Trastuzumab in HER2-Positive Breast Cancer, N. Engl. J. Med, vol. 365, no. 14, pp. 1273–1283, https://doi.org/10.1056/NEJMoa0910383

4. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer | NEJM. Accessed: Nov. 07, 2022. [Online]. Available: https://www.nejm.org/doi/10.1056/NEJMoa052306?url_ver=Z39.88-2003&_id=ori:rid:crossref.org&_dat=cr_pub%20%200www.ncbi.nlm.nih.gov

5. Romond EH et al (2005) Oct., Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer, N. Engl. J. Med, vol. 353, no. 16, pp. 1673–1684, https://doi.org/10.1056/NEJMoa052122